Nucynta Generic Launch

Introduction

Generic medications contain the exact same strength and active ingredient as their brand counterparts. They exert the same therapeutic effect on the body and carry all of the same dosing recommendations, as well as safety and use precautions. The main differences are that they are manufactured by different drug companies and contain different inert (inactive) ingredients.

What is happening?

Nucynta® (Tapentadol) is an opioid medication. There are both immediate-release versions taken every four to six hours as needed for breakthrough pain and extended-release versions taken chronically every twelve hours for around-the-clock pain relief. Nucynta® is FDA-approved to treat severe pain and neuropathic pain (especially diabetic neuropathy). Nucynta® is a C-II controlled substance and has a high potential for abuse/misuse. It is also subject to strict dispensing regulations due to this classification.

On February 25th, 2026, the first available generic for immediate release Nucynta® was released as Tapentadol tablets. And on March 12th, 2026, the first available generic was launched for the extended-release formulation as well.

Availability

As the generic was just launched, it can be expected that they will soon be available (if not already) for pharmacies to purchase and stock for use. However, as with any new generic launch, sometimes it can take weeks to months for some pharmacies to be able to get a supply of the new product. At the beginning of the generic launch, we consult with the dispensing pharmacies regarding stocking.

Cost Comparison

New generics are less expensive than their brand counterparts. Please note that cost estimates are based on the Average Wholesale Price (AWP) of medications, which are fluid and based upon many factors. In general, generic medications do not rapidly drop in price to yield a significant cost savings until enough time (months or years) has passed to allow for multiple generic manufacturers to enter the market with their approved products. This process increases competition and therefore decreases the price.

Estimated cost savings

Substituting the brand Nucynta with the generic formulation would currently save between $ 0.80-$1.25 per tablet for the immediate release formulations, and between $0.84-$3.19 per tablet for the extended-release formulations.

Potential cost savings: For example, a 30-day dispense quantity of # 60 tablets, substituting with the generic would result in a cost savings of approximately $48-75 for the immediate release versions, and approximately $50-191 for the extended release. In 2025, our average fill of brand Nucynta® was priced around $2,000.

Relevance To Injury Claims

Nucynta has become one of the more common medications prescribed to injured workers requiring opioid therapy. Across our book of business, Nucynta represented 2% of total opioids dispensed, but accounted for approximately 20% of total opioid spend. Many patients use both formulations for acute and chronic pain.

CorVel Clinical Team Input

Our clinical team regularly receives inquiries from clients regarding when generic versions of this medication will be launched. We have been closely monitoring the generic status of this medication. This new generic formulation is a welcome release for use with relevant injury claims. It will offer a cost savings while providing a chemically identical treatment to the pre-existing brand formulation of Nucynta®. The main difference between brand components and their generic counterparts is that they have different inactive ingredients. Allergies should always be noted, as a patient may be allergic to inactive ingredients in a generic formulation that are not present in the brand product.

CorVel Action Plan

If a prescription for brand Nucynta® presents on a pharmacy card, we will enforce generic dispensing. Pharmacy systems automatically substitute generic formulations for brand medication orders when processed at the pharmacy. A brand product would only be dispensed if a physician ordered the prescription to be dispensed as written (DAW), meaning the pharmacy cannot legally substitute it as a generic. In that case, we would enforce our brand with available generic DAW workflow, which involves Letters of Medical Necessity Requests, as well as provider and pharmacy outreach. As the generic product still carries a high price point compared to other generic opioid medications, we will still attempt to convert these prescriptions to more cost-effective opioid medications. Tapentadol will remain a non-formulary medication that requires a prior authorization.